Psychedelic drug development is entering a critical phase as regulatory expectations evolve and clinical programs scale across compounds such as MDMA, ketamine, and psilocybin. While the therapeutic promise is significant, sponsors face unique challenges in trial design, safety oversight, and regulatory engagement that demand specialized expertise.

This resource outlines how MMS supports sponsors across the full psychedelic development lifecycle—from early regulatory strategy and KerusCloud®-enabled study design through biometrics execution, safety and medical writing, NDA coordination, and REMS planning.

Designed for clinical development, regulatory affairs, and data science leaders, this overview highlights how MMS helps sponsors mitigate risk, improve data quality, and confidently engage with regulators in one of the industry’s most complex therapeutic areas.

This fact sheet explains how MMS provides end-to-end data, biometrics, and regulatory support for psychedelic drug development.

Key Benefits / What You’ll Learn

• Understand MMS’s full-lifecycle support model for psychedelic therapies.
• See how KerusCloud®-enabled trial design reduces risk early in development.
• Learn how MMS manages complex data, subjective endpoints, and safety oversight unique to psychedelic trials.
• Evaluate MMS’s regulatory experience with NDAs, FDA meetings, and Advisory Committees.
• Reference MMS’s depth of experience across MDMA, ketamine, and psilocybin programs.

Why Psychedelic Development Requires Specialist Guidance

Psychedelic drug development presents unique scientific, operational, and regulatory challenges that differ materially from traditional CNS programs.

MMS brings deep expertise in:

• Non-standard and highly subjective endpoints, including guided psychedelic therapy outcomes.
• Data quality risks and failure modes inherent in behavioral and experiential assessments.
• Complex patient dynamics, including comorbid substance use and compliance challenges.
• Heightened regulatory scrutiny, requiring proactive planning and evidence-based oversight.

Psychedelic trials require specialist data and regulatory expertise due to complex endpoints, safety considerations, and evolving FDA expectations.

End-to-End Psychedelic Development Capabilities

MMS supports psychedelic programs across the full development lifecycle:

• Regulatory strategy and pathway planning
• KerusCloud®-enabled study design optimization
• End-to-end biometrics execution
• Safety and medical writing
• NDA coordination and submission leadership
• REMS design and implementation
• Advisory Committee preparation and FDA meeting support

MMS has hands-on experience leading NDA applications for psychedelic therapies, including active participation in formal FDA and Advisory Committee proceedings.

Technology-Enabled Oversight and Risk Mitigation

MMS integrates proprietary technology to manage complexity and mitigate development risk:

• Datacise® provides real-time oversight of operational and data quality risks.
• KerusCloud® enables simulation-driven trial design and scenario evaluation.

Datacise® and KerusCloud® enable proactive oversight and risk mitigation in psychedelic drug development.

Advance Psychedelic Drug Development With Proven Regulatory and Data Expertise

Download your Fact Sheet today ↓

Strategic and Academic Collaboration

MMS works closely with:

• Academic key opinion leaders
• Veterans Affairs (VA) system
• Department of Defense (DoD)
• Public-sector stakeholders and industry consortia

MMS experts are recognized thought leaders, contributing to guidance documents, publications, and conference presentations shaping psychedelic development standards.

Demonstrated Leadership in Psychedelic Development

• Largest experience base in data and regulatory support for psychedelic therapies
• Experience across MDMA, ketamine, and psilocybin programs
• Applications reviewed by the Psychopharmacologic Drugs Advisory Committee
• Deep operational insight into FDA’s 2023 psychedelic drug development guidance

MMS is an award-winning, data-focused CRO with a 19-year track record, global delivery across four continents, and recognized leadership in complex regulatory programs, including psychedelic drug development.

A focused, authoritative reference for teams navigating the scientific and regulatory complexity of psychedelic drug development.
Designed for fast review, internal alignment, and confident decision-making.